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The cyclic guanosine-3′,5′-monophosphate (cGMP)-dependent pro-
tein kinase (PKG) was identified >25 y ago; however, efforts to
obtain a structure of the entire PKG enzyme or catalytic domain
from any species have failed. In malaria parasites, cooperative acti-
vation of PKG triggers crucial developmental transitions throughout
the complex life cycle. We have determined the cGMP-free crystal-
lographic structures of PKG from Plasmodium falciparum and Plas-
modium vivax, revealing how key structural components, including
an N-terminal autoinhibitory segment (AIS), four predicted cyclic
nucleotide-binding domains (CNBs), and a kinase domain (KD), are
arranged when the enzyme is inactive. The four CNBs and the KD
are in a pentagonal configuration, with the AIS docked in the sub-
strate site of the KD in a swapped-domain dimeric arrangement. We
show that although the protein is predominantly a monomer (the
dimer is unlikely to be representative of the physiological form), the
binding of the AIS is necessary to keep Plasmodium PKG inactive. A
major feature is a helix serving the dual role of the N-terminal helix
of the KD as well as the capping helix of the neighboring CNB. A
network of connecting helices between neighboring CNBs contrib-
utes to maintaining the kinase in its inactive conformation. We pro-
pose a scheme in which cooperative binding of cGMP, beginning at
the CNB closest to the KD, transmits conformational changes around
the pentagonal molecule in a structural relay mechanism, enabling
PKG to orchestrate rapid, highly regulated developmental switches
in response to dynamic modulation of cGMP levels in the parasite.
cyclic GMP | signal transduction | malaria | Plasmodium | structure
Malaria remains a serious global health problem, with closeto 500,000 deaths and hundreds of millions of new infec-
tions annually. Reports of prolonged parasite clearance times
and treatment failures using artemisinin combination therapies
(ACTs) are increasingly frequent in parts of Southeast Asia (1).
New targets to supply the next generation of antimalarial drugs
are being studied with urgency to tackle this growing trend,
particularly in anticipation of the spread of ACT resistance to
Africa. Among promising drug targets are protein kinases enco-
ded by the genomes of the Plasmodium parasites responsible for
the disease (2). Previous work has demonstrated that one par-
ticular kinase, known as cyclic guanosine-3′,5′-monophosphate
(cGMP)-dependent protein kinase, or protein kinase G (PKG), has
essential roles in multiple stages of the parasite life cycle. Selective
pharmacological inhibition of Plasmodium falciparum PKG
(PfPKG) blocks the egress of merozoites (3) and gametes (4)
from erythrocytes, as well as inhibits the motility of ookinetes in
the mosquito (4, 5) and invasion of hepatocytes by sporozoites
(6). PKG orchestrates the progression of these key differentiation
events in Plasmodium via a complex system of second messenger
signaling, involving phosphoinositide metabolism and calcium
mobilization (7, 8). A phosphoproteomic study has linked PfPKG
activity to 107 phospho-sites on 69 different proteins in the P. fal-
ciparum proteome, including some implicated in invasion and egress
(9). Regulation of cGMP has also been associated with calcium flux
and egress in the related apicomplexan pathogens Toxoplasma and
Eimeria (10). These lines of evidence support PKG as a promising
target for antiparasitic drug discovery, as well as a gateway to a
deeper understanding of parasite signaling.
The cellular functions of parasite PKG are regulated by allo-
steric and cooperative binding of cGMP (11), similarly to how
mammalian PKG is activated. Allostery and cooperativity are
also the hallmarks of another eponymous member of the AGC
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subfamily of protein kinases, adenosine 3′,5′-cyclic mono-
phosphate (cAMP)-dependent protein kinase (PKA). The reg-
ulatory and catalytic subunits of PKA are distinct, separately
encoded proteins that form tetrameric complexes composed of
two regulatory subunits and two catalytic subunits (R2C2) (12, 13).
In contrast, the regulatory and catalytic domains of PKG
coexist within a single polypeptide encoded by a single gene. In
mammals, this assembly contains two cyclic nucleotide-binding
(CNB) sites, compared with the four CNB domains in apicom-
plexan PKG isoforms (14). Even though PKA and PKG were
both among the earliest kinases identified, understanding of how
the structural divergence of PKG from PKA affects cGMP-
mediated allostery and cooperativity (15) in different organ-
isms is at best fragmentary.
Structural biology is an essential tool in the study of protein
kinases. PKA, the first to be crystallized (16), is the archetypal
protein kinase in structural and mechanistic studies. There are
now a number of PKA structures revealing the standalone catalytic
and regulatory subunits, as well as the engaged R1C1 dimers and
R2C2 tetramers (12, 17, 18). In contrast, for both mammalian and
parasite PKG, only the structures of isolated regulatory domains
have been reported (19–26). A report disclosing the structure of
one of the cGMP-binding domains of PfPKG (CNB-D) identified
a triad of residues in its C-terminal helix that are essential for
regulation of enzyme activity (23). How this domain interacts with
the remainder of the PKG structure and, more generally, how
Plasmodium PKG mediates cGMP signaling are unknown.
Here, we describe the complete atomic structure of PKG from
two human malaria parasite species, P. falciparum and Plasmo-
dium vivax. To date this has not been achieved for PKG from any
other organism. The resulting structures provide insights into
how the CNBs interact with the kinase domain (KD) to keep it in
a largely autoinhibited state and how the parasite maintains its
cGMP signaling system in the off state. Combining our structural
findings with biophysical and biochemical data allows us to
propose a structural relay model of cooperative activation of
parasite PKG that may also have important implications for
regulation of mammalian PKG.
Results
Plasmodium PKG Is a Member of a Distinct Class of PKG Enzymes.
Mammalian PKGs are classified into types Iα, Iβ, and II (also
known as PKG-Iα, -Iβ, and -II), all featuring a single polypeptide
comprising a regulatory domain of two CNBs fused to the N-
terminal flank of a single catalytic KD. Known to form inactive
dimeric holoenzymes when free of cGMP, they have an effective
regulatory stoichiometry (i.e., a CNB-to-KD ratio) of 4:2, similar
to that in a PKA R2C2 tetramer. In contrast, PKG enzymes of
Plasmodium and other apicomplexan parasites have an extended
N-terminal domain that features four CNBs (Fig. 1A) upstream
of the KD and are monomeric (27), resulting in an effective
regulatory stoichiometry of 4:1. There is thus significant struc-
tural divergence between Plasmodium and mammalian PKGs,
prompting us to formally define kinases with more than two in-
tegrated cGMP-binding sites as type III or PKG-III.
A search of the National Center for Biotechnology Information
(NCBI) Protein database (https://www.ncbi.nlm.nih.gov/protein) led
us to identify multiple subclasses of type III PKGs. In all apicom-
plexan PKGs examined, one of the four CNBs is similar in sequence
to canonical cGMP-binding domains but lacks one or more critical
residues (23). We refer to such a domain as a pseudo-CNB (pCNB)
and the corresponding PKG as type IIIα. There are organisms,
including green algae such as Ostreococcus, in which PKG contains
four cGMP-binding CNBs—that we call type PKG-IIIβ. Finally,
type IIIγ PKGs, such as some found in Paramecium and Tetrahymena
(both of which have multiple paralogues of PKG), contain three
predicted CNBs. Type III PKGs are observed only in protist
genomes. In contrast, animals possess only types I and II PKGs. The
architectures of these subtypes, along with those for types I and II as
well as PKA, are shown for comparison in Fig. 1A.
Plasmodium PKG Adopts a Pentagon-Shaped Architecture. We
expressed and purified full-length recombinant PfPKG and P.
vivax PKG (PvPKG). They crystallized as dimers in orthorhom-
bic and monoclinic space groups respectively, and both yielded
2.4-Å apo structures [Fig. 2A and SI Appendix, Fig. S1 and Table
S1; Protein Data Bank (PDB) ID codes: 5DYK and 5DYL]. The
two orthologs are 92% identical in sequence; furthermore,
alignment of their structures resulted in rmsds of 0.8 Å—
representing negligible differences (SI Appendix, Fig. S1). PvPKG
also cocrystallized with adenylyl-imidodiphosphate (AMPPNP),
a nonhydrolyzable analog of adenosine triphosphate (ATP),
again as a dimer (PDB ID code 5DZC; 2.3 Å; SI Appendix, Table
S1). In the ensuing description, unless stated otherwise, impor-
tant details are common to all of the structures. To ensure
clarity, important differences in residues are mentioned in the
text and highlighted in an alignment of the sequences of the two
orthologs (SI Appendix, Fig. S2).
In the Plasmodium PKG crystal structures, each protomer in the
dimers can be described as four CNBs, which, together with the N
lobe of the KD, form a pentagonal arrangement (Fig. 1 B and C),
with the KD C lobe locked in the center. CNB-A and -B make
direct contact with and constrain (and are constrained by) the C
lobe of the KD from functionally essential movement (Fig. 1 B
and C), resulting in a substructure of these three domains that
closely resembles the R-C heterodimer of PKA (Fig. 1D) (12).
Interestingly, all three Plasmodium structures display a swapped
domain arrangement, in which the N terminus of each protomer in
the dimer interacts with the active site of the other (Fig. 2A).
The N-Terminal Segment of Plasmodium PKG Has an Autoinhibitory
Role. To study the significance of occupation of the Plasmodium
PKG active site by the N-terminal residues, we generated a trun-
cated form of PfPKG which starts at position S30, and so lacks the
swapped N-terminal motif (Fig. 2A). Kinase activity assays (Fig.
2B) showed that the truncated recombinant enzyme (PfPKG–
ΔAIS) had equivalent activity to the full-length protein in the
presence of cGMP; however, only the truncated form demon-
strated activity in the absence of cGMP (Fig. 2B). This suggested
an inhibitory role for the N-terminal segment of Plasmodium PKG
that is likely similar to that performed by an equivalent motif in
PKA (18) and human PKG (28). Accordingly, we validated that the
trans-binding of the N-terminal motif does not contribute to in-
hibition of the kinase (Fig. 2D), suggesting an intrasteric mode of
action as demonstrated by preincubation of the catalytically active
N-terminally truncated form of PfPKG (PfPKG–ΔAIS) with an
inactive full-length PfPKG–E589A enzyme (ATP-binding-site
mutant). Furthermore, the activity curve of PfPKG–ΔAIS is sig-
moidal, with a Hill coefficient of 1.9 (Fig. 2C), indicative of the
same homotropic positive cooperativity reported for full-length
PKG in Plasmodium and other type IIIα PKGs.
The dimeric crystal structure was unexpected and required in-
vestigation of its relevance, which was performed by using multi-
angle laser light scattering (full-length PfPKG and PvPKG; SI
Appendix, Fig. S3), analytical ultracentrifugation (full-length PfPKG
and PvPKG; full-length PfPKGwith AMPPNP; and PfPKG–ΔAIS;
SI Appendix, Fig. S4), and immunoblot analysis of epitope-tagged
native PfPKG from parasite lysates (SI Appendix, Fig. S5). In all
cases, the dimeric fraction ranged from very little (e.g., the strongest
dissociation constant was found to be ∼32 μM in area-under-the-
curve experiments, indicative of a very small dimer fraction) to
undetectable. Collectively, the activity assays and biophysical char-
acterizations indicate that (i) cGMP is required for full activation of
PfPKG; (ii) the interaction between the N terminus of the protein
and the active site is required for complete autoinhibition (but not
for cooperativity), prompting us to name this region the auto-
inhibitory segment (AIS) for parasite PKG; and (iii) Plasmodium
PKG is predominantly monomeric [consistent with what has been
reported for the closely related Eimeria PKG (29)]—i.e., the
swapped-domain dimer is unlikely to be representative of the
physiological form of the inactive or active protein. To date, our
attempts to crystallize the AIS-truncated form of Plasmodium PKG,
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the monomeric state of the full-length (or truncated) protein, or its
cGMP-bound configuration have been unsuccessful.
Deviations of the KD of Plasmodium PKG from the PKA Catalytic
Subunit Have Functional Implications. Similar to PKA, the KD of
PfPKG adopts a classical bilobal structure flanked by an N-terminal
helix (αAK) and a C terminus (Fig. 3A). Despite being locked in an
overall autoinhibited state, PfPKG–KD surprisingly exhibits many
structural features of an active kinase, including: (i) interaction
between the catalytic lysine K570 and E589 (on helix αCK; Fig.
3A); (ii) positioning of the helix αCK toward the ATP-binding site
(Fig. 3A); (iii) an open (active) conformation of the activation
loop (Fig. 3A); and (iv) intact hydrophobic spines (Fig. 3B). We
further note that, compared with fully closed KDs (e.g., PDB ID
Fig. 1. Plasmodium PKG displays a pentagonal architecture. (A) PKA is made up of two proteins: The regulatory subunit (R) contains CNB-A and -B and the
catalytic subunit (C) includes an N-terminal helix (pink), the classical bilobal KD (yellow and green), and a C terminus (brown). Mammalian PKG-I and -II feature a
PKA-like catalytic KD concatenated with a tandem of CNBs. In type III PKG, there are three or more CNB or CNB-like domains. PfPKG, an exemplar of type IIIα,
contains four integrated CNBs, one of which does not bind cGMP. In contrast, type IIIβ PKG has four functional cGMP-binding sites, while type IIIγ members have
exactly three CNBs. An inhibitory substrate sequence flanks the N terminus of the first CNB in each case. In PKA and mammalian PKG, there is an additional region
of dimerization and docking motifs. The absence of this in type III PKGs suggests that they are likely monomeric. (B) Surface rendering of PfPKG colored as in A.
PfPKG adopts a pentagonal architecture composed of the four CNB domains and the N lobe KD in the outer rim, and the C lobe KD locked in themiddle. The CNB-
A and -B domains make contact with the C lobe of the KD, similar to what is seen in all PKA heterodimers. CNB-D also makes contact with the C terminus (brown),
whereas pCNB-C does not make direct contact with any part of the KD. CNB-D shows a unique arrangement not seen in PKA, making contacts with both the N
lobe and the C terminus. (C) Structure of PfPKG drawn in cartoon representation. The long helix connecting CNB-A and -B is similar to that seen in PKA. We
hypothesize that, inside the parasite, the AIS would occupy the KD’s active site to form a fully autoinhibitedmonomer. (D) Overlay of PfPKG and PKA heterodimer
(PDB ID code 2QCS; in gray) depicts structural homologies. CNB-A, -B, and the KD form a substructure that closely resembles the heterodimer of PKA.
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Fig. 2. Biochemical and biophysical assays. (A) The representation of the asymmetric unit from the PfPKG crystal illustrates a swapped domain dimer ar-
rangement in which the N terminus of each protomer interacts with the active site of the other. The pseudosubstrate (red and gray surfaces) from the dimeric
partner is shown binding (and inhibiting) the substrate site between the N and C lobes. These interactions contribute to autoinhibition of the protein. (B) The
AIS inhibits PKG activity in vitro. In the absence of cGMP, the full-length protein exhibits negligible activity, whereas the truncated mutant protein (AIS
removed) was partially active. Both samples were equally active in the presence of cGMP. wt, wild type. (C) Both the full-length and AIS-truncated constructs
demonstrate homotropic positive cooperativity (Hill coefficient is 1.7 for the full-length sample and 1.9 for the truncated sample) when activated by addition
of cGMP. The AIS is not required for full kinase activity under cGMP activation. (D) The AIS functions intrasterically to suppress kinase activity. The kinase
activity of the catalytically active PfPKG–ΔAIS truncation mutant (1 μM) is monitored in the absence of cGMP with incremental concentrations of full-length
PfPKG–E589A dead enzymes (1–8 μM). The AIS of the dead enzyme does not occupy/inhibit the active site of PfPKG–ΔAIS. (E) Using the dimeric structure to
hypothesize a model for the autoinhibitory domain of monomeric PfPKG. The KD of one PfPKG-a is shown in yellow and green surface, along with its
adjacent CNB-A domain aligned with the CNB-A of all four types of PKA (PDB ID codes 3FHI, 2QVC, 4DIN, and 4X6Q; all drawn in gray). The AIS of PfPKG-b
(dark blue) overlays with the inhibitory segment of all four PKA structures (RIα in purple, RIIα in cyan, RIβ in pink, and RIIβ in yellow). In a monomer, we
hypothesize that PfPKG-a would extend its own AIS (colored in red) in the same position (instead of in the KD of PfPKG-b). In all cases, a short helical overpass
hovers above the long helix connecting the first two CNBs follows this inhibitory motif. The overpass of PfPKG-b is shown here to indicate how PfPKG-a might
be different structurally as a monomer. It is also interesting that all of the structures are closely aligned from helix X:N onward, including Plasmodium PKG.
This, along with all experimental data, supports the relevance of the rest of our crystal structure
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code 1ATP), the KD in all our structures can be described as par-
tially open, with the AMPPNP-bound structure less open than the
nucleotide-free versions.
All three of our Plasmodium PKG structures feature an activa-
tion loop that is both in its open conformation and unphosphory-
lated—an uncommon combination previously observed in rho
kinases and rho-associated kinases (30) such as ROCK and MRCK.
This is in contrast to PKA (and other members of the AGC sub-
family and the majority of available S/T kinases crystallized with the
activation loop in the open position), where T197 is phosphorylated
(16). In recombinant PfPKG, we found that T695 (homologous to
T197 in PKA) would become phosphorylated in the presence of
cGMP, Mg2+, and ATP. The same modification has also been
identified in a phosphoproteomics study (31). On the other hand,
we found that the recombinant protein maintained the same
activity profile (i.e., inactive without cGMP and fully active with
cGMP) when T695 was mutated to either Ala or Gln (SI Ap-
pendix, Table S2). Rationalizing the significance of this putative
phosphothreonine requires additional experiments.
The C terminus is a hallmark of AGC kinases (32) and an es-
sential cis-regulatory component. It is partially disordered in our
PfPKG structure, similar to apo PKA structures (e.g., PDB ID code
1CTP). It is made up of four segments (Fig. 3C)—helix αI, the C-
lobe tether (CLT), the active-site tether (AST), and the N-lobe
tether (NLT). In the CLT, the first proline in the PxxP motif in
PKA (and PKC)—known to play a role in interlobe movement—is
conserved in PfPKG (Fig. 3 C and D). In the AST, PfPKG uses a
motif starting with tyrosine (Fig. 3 C and D) to interact with the
ATP-binding pocket, similar to the role of the FDDY motif in
PKA, as well as in mammalian PKG (32). In the NLT, the hy-
drophobic motif (HF) features WxxxF in place of FxxF (Fig. 3C), a
minor deviation conserved in all types of PKG. In our structure,
W849 is disordered, but F853 engages a hydrophobic pocket at the
top of the N lobe (Fig. 3D), similar to what has been reported in
Fig. 3. KD of PfPKG. (A) KD of PfPKG isolated with the
rest of the protein hidden. The activation loop is high-
lighted in blue in part to show that it is in its active
conformation, but does not contain a phosphorylated
site. The residue T695 is unphosphorylated, which is
unusual for an active AGC kinase structure. The in-
teraction between K570 and E589, the position of the
helix αAK, and the conformation of the activation loop
are all characteristic of an active KD. (B) Intact hydro-
phobic spines are characteristic of an active KD. The C
spine, shown here in yellow, comprises V555, A568,
L626, I670, L671, L672, C725, and F729. It is broken in
two sections because this crystal structure is missing ATP
or a similar ligand. The R spine, made up of T593, L604,
Y662, F683, and D718, is in red. (C) Similar to human
PKA, the C terminus of PfPKG comprises helix αI, the
CLT, the AST, and the NLT. (D) Two prolines (P813 and
P814) anchor PfPKG’s CLT in a similar fashion as the
PxxP (P314, F315, and P317) motif does in PKA. The
FDDY motif in PKA is replaced by a single tyrosine
(Y822) in PfPKG. The NLT in PfPKG comprises the motif
WDIDF. In the structure, W849 is disordered, but
F853 inserts itself in a hydrophobic pocket at the top of
the N lobe of the KD. (E) The C tail of the KD (residues
in brown) makes water-mediated contacts with CNB-D
(cyan). (F) The main structural deviation between PKA
and PKG is the N-terminal helix, as seen in the super-
position of the catalytic subunit of PKA from mouse
(PDB ID code 1ATP; αAK in gray) and the KD of PfPKG
(αAK in beige). (G) In PfPKG-KD, helix αAK interacts with
both lobes of the KD as well as the C terminus, with a
number of interactions maintaining the KD in an open
conformation and the overall protein in its auto-
inhibited state. These interactions include a π-bond
between H524 on helix αAK and R809 on the C tail,
with the latter secured by salt bridges with P599 in the
N lobe and D673 and D675 in the C-lobe.
El Bakkouri et al. PNAS Latest Articles | 5 of 10
M
ED
IC
A
L
SC
IE
N
CE
S
PKA (32). In addition, the C tail makes interactions with the N-
terminal helix αAK and water-mediated contacts with CNB-D
(Fig. 3E), the former of which is described below.
The N-terminal helix, αAK in PKG, is the only major structural
element to deviate in position noticeably from its PKA coun-
terpart (Fig. 3F). As shown in Fig. 3G, αAK in PfPKG makes
multiple contacts with the N and the C lobes, some of which
involve R809 as well as the C terminus of PfPKG–KD, and none
of which have been observed in PKA. The contact between the
two termini features a salt bridge between R528 and D597 as
well as a π-bond between H524 and R809. Substitution with al-
anine of H524, R528, or R809 (Pf PKG–H524A, –R528A,
and –R809A; SI Appendix, Table S2) resulted in polypeptides
that were either unstable (i.e., prone to precipitate) or inactive,
establishing the significance of these interactions.
Structures of the CNB Domains of PfPKG Explain Their Distinct cGMP-
Binding Properties. The Plasmodium PKG structures contain four
distinct CNBs. All four share the reported canonical fold of CNB
domains (33, 34), including the N3A bundle (helices αN and αA,
with a 310 loop in between) in the N terminus, an eight-stranded
β-barrel, followed by a C-terminal hinge made up of helices αB
and αC (Fig. 4A). In the middle of the β-barrel of CNB-A, -B, and -D
is a 24-residue-long phosphate-binding cassette (PBC) featur-
ing the universally conserved glutamate and arginine residues, as
well as a short flexible helix, sometimes referred to as the B′-helix
(35). Their interactions with cGMP were determined by iso-
thermal titration calorimetry (ITC), revealing 14, 17, and 0.17 μM
binding affinities for the CNB-A, -B, and -D when expressed as
standalone recombinant protein samples, respectively (Fig. 4B).
The third CNB, pCNB-C, stands out because a hydrophobic
network consisting of Y363, H373, F371, and F359 occludes the
cGMP-binding pocket. Accordingly, we were not able to detect
any binding activity toward cGMP due to a degenerate binding
site (Fig. 4B). Furthermore, D361 and P370 take the places of
glutamine and arginine, respectively, which are universally con-
served in determined cAMP- and cGMP-binding CNBs (35).
Our crystal structures and binding affinities strongly support
previous suggestions that only three of the four CNB domains in
Plasmodium PKG bind cyclic nucleotides (36).
CNB-D stands out from the other regulatory domains in a
different way; its C-terminal helices (αBD and αCD) are closer to
their cGMP-capping positions than in the other CNB domains,
as confirmed by comparison with existing structures of cGMP-
and cAMP-binding CNBs (SI Appendix, Fig. S6). This domain
also has the highest affinity for cGMP by two orders of magni-
tude, compared with CNB-A and -B (Fig. 4B), such that this
regulatory unit is likely the first domain in PfPKG to become
occupied as the cellular concentration of cGMP rises. This is
consistent with a model proposed by Kim et al. (23).
Interdomain Contacts Provide Insight into Regulation of Plasmodium
PKG by cGMP. To study the interaction between different domains
in the Plasmodium PKG pentagon, we divided the structure into
two overlapping halves. The left half consists of CNB-A, -B, and
the KD. As shown in Fig. 1D, this trio of domains is arranged in a
way that is highly similar to the PKAR:PKAC heterodimer.
Closer examination reveals that some of PKA’s interdomain
contacts, previously cataloged into four sites (12, 18), are also
conserved in Plasmodium PKG, as described immediately below.
In site 1, the basic AIS in PfPKG is docked against the activation
loop of the KD in a manner reported for PKA, with key lysines
(K15 and K16) replacing homologous arginines (R94 and R95 in
PKAR–RIa) in interacting with the P+1 loop on the KD (SI Ap-
pendix, Fig. S7A). Sites 2 and 3 (SI Appendix, Fig. S7B) are the main
interface where CNB-A and -B meet the activation loop, the
P+1 loop, and the C lobe of the KD. Key contacts include π-bonds
between K157 and Y694 as well as F164 and R692 (the latter sup-
ported by a hydrogen bond between N190 and R692). Furthermore,
there is a hydrophobic cluster involving the substrate-binding loop
(L696), the C lobe (F747), and CNB-A (I127 and H128). These in-
teractions mutually constrain the lower part of the KD and the first
cGMP-binding domains similarly to what has been observed in the
PKA heterodimer (12, 18, 37) [e.g., the R194C–D241R–D267R triad
in the PKAC/PKAR–RIa heterodimer (18) is replaced by
R692:F164:N190 in PfPKG]. To explore the significance of these
interactions, we generated mutants of PfPKG and investigated their
activity (SI Appendix, Table S2). The resulting recombinant proteins
of mutants with K157, F164, N190, or Y694 modified to alanine were
either unstable or inactive. On the other hand, mutants with
H128 and R692 similarly substituted remained stable and active.
In PKA, site 4 is the region of interaction between domain B
(specifically helix αB) and the KD (specifically helices αH and
αI). This site has been fully described in holoenzymes comprising
PKAR–RIa (12) and –RIIa (37). Intriguingly, there is negligible
contact in this area observed in the Plasmodium PKG structures.
This is likely due to the fact that this contact, required in PKA to
secure the position of CNB-B, is obviated by the pentagonal
single polypeptide arrangement in Plasmodium PKG.
In addition to PKA-like interactions, there are parasite-specific
interdomain contacts observed in the Plasmodium PKG structures,
which are represented in the right half of the pentagon (consisting
of pCNB-C, CNB-D, and the KD). Notably, αAK is not only the
N-terminal helix of the KD, but also the C-terminal αC helix of
CNB-D. In this conjoined arrangement, αAK engages CNB-D,
particularly its PBC in multiple contacts. This includes a π-bond
between R528 and Y417 that is supported by a salt bridge between
Q532 and R528 (SI Appendix, Fig. S7C). In addition, a salt bridge
between D533 and R484 (of the PBC of CNB-D) also contributes
to the interaction between αAK and the PBC. Not surprisingly, a
mutant form of PfPKG with R484 replaced by alanine was enzy-
matically inactive (SI Appendix, Table S2). These interactions,
along with other contacts between CNB-D and the C terminus,
constitute site 5, which is not found in PKA.
Interestingly, in Plasmodium PKG, the junction of CNB-A and -B
conserves the long connecting helix observed in PKA (Fig. 1C andD).
However, between CNB-B and pCNB-C, as well as between pCNB-C
and CNB-D (Fig. 1C), this helix is twisted, which results in two helices:
the C-terminal helix (αCB) of the first CNB and the starting helix of
the second CNB (αN). In this arrangement, the helix αN makes
contact with the preceding CNB, including interactions with the PBC.
These connecting helices not only constrain neighboring domains, but
are likely also the mediator of interdomain communication, propa-
gating movement in one domain to the other. To further investigate
the cGMP allosteric regulation transmitted along connecting helices,
we attempted solving the cocrystal structures of other isolated CNB
domains bound to cGMP, including CNB-A and -B. The PfCNB-A
domain bound to cGMP yielded high-quality crystals diffracting to
1.65-Å resolution (PDB ID code 5E16) and illustrates conformational
changes imposed by the repositioning of the helix αBA to lock the
cGMP in place within the binding pocket (Fig. 4E). This conforma-
tional change is accompanied by a larger displacement of the con-
necting helix αCA (42° rotation) that is anticipated to redraw the
neighboring interaction between CNB-A and KD in the full-length
protein (Fig. 4F). Especially, we denote the probable rearrangement
of key interactions upon cGMP activation, particularly the K157–Y694
π-bond interaction (site 2) between the connecting helix αCA and the
activation loop in the immediate vicinity of the kinase active site (Fig.
4 E and F and SI Appendix, Table S2). This clearly suggests a mech-
anism by which conformational modifications induced by binding of
cGMP to one CNB could be relayed to adjacent domains.
Discussion
In mechanistic studies of protein kinases, obtaining their inactive
and active structures are important landmarks representing two
key states in a regulatory or signaling system. Using a combination
of structural biology with biochemical and biophysical assays, our
study has established that cGMP-free Plasmodium PKG is a mo-
nomeric protein held in an autoinhibited state by four main fea-
tures: (i) intrasteric regulation effected by the cis-binding of the
AIS in the substrate site; (ii) immobilization of the two lobes by
the CNBs using a number of interdomain contacts; (iii) interaction
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Fig. 4. The CNBs of PfPKG. (A) Surface rendering of the four PfPKG CNB domains, shown with their cGMP-binding pocket in gray surfaces. A cGMP molecule is
manually docked in their putative binding sites for illustration. The third CNB, pCNB-C, is similar overall to the other CNBs, except for the cGMP-binding pocket,
which is occluded due to a network of hydrophobic residues. (B) ITC binding curves for the CNB-A, -AB, -C, and -D constructs to cGMP. Upper and Lower display the
ITC titration curves and the binding isotherms, respectively. As the CNB-B domain did not yield soluble recombinant protein, its binding activity was tested within a
CNB-AB tandem construct. The binding affinity for the CNB-A, -B, and -D domains is 1.4, 1.7, and 0.17 μM, respectively; the CNB-C domain does not bind to cGMP.
(C) Alignment of the CNB-D in our apo PfPKG structure (in color) with the cGMP-bound costructure (PDB ID code 4OFG; in gray) shows that the helix αCD un-
dergoes noticeable displacement when cGMP is engaged. The triad (R484, Q532, and D533) key to activation of the enzyme is also displaced to (R484′, Q532′, and
D533′). (D) Orthogonal representation of C. (E) Alignment of the CNB-A in our apo PfPKG structure (in color) with the cGMP-bound costructure (PDB ID code 5E16;
in gray) shows the rearrangement of helices αBA and αCA in response to cGMP binding. Upon cGMP activation, the helix αCA undergoes a large rotation of 42°, but
does not contribute to cGMP capping as observed in PKA and PfCNB-D; instead, the cGMP ligand is stabilized by interactions with the backbone of helix αBA. (F)
Alternative representation of E that includes the CNB-A neighboring domains of PfPKG (apo form). The cartoon illustration depicts rearrangements of the
connecting helix αCA relative to the CNB-B and kinase activation loop, with the disruption of the important K154–Y694 π-bond interaction.
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between the N-terminal helix and the C terminus of the KD in a
mutually locking arrangement; and (iv) arrangement of connecting
helices between CNB-B and pCNB-C, pCNB-C and CNB-D, and,
most significantly, the conjoined helix between CNB-D and the
KD. To the best of our knowledge, the last two features are not
only distinct from PKA, but entirely unique among kinases to date.
Intrasteric Regulation Is Mediated by an N-Terminal AIS. Auto-
inhibition in mammalian PKA and PKG involves interactions
between the regulatory and catalytic domains (18, 38). The
proposed conformational changes mediated by cGMP binding
are thought to release PKG from its autoinhibition and allow it
to become active. Although the autoinhibitory domains of PKA
and PKG do not have a universally conserved sequence, they all
share a consensus small residue (most commonly glycine, re-
placeable by alanine, serine, or valine; underlined in SI Appendix,
Fig. S7A) in the so-called P0 position, where a phosphorylation
target—namely, serine or threonine—might be found in a
pseudosubstrate peptide (e.g., the pseudosubstrate bound in the
AIS site in one of the first PKA structures). Alignments of se-
quences and structures indicate that this residue (Ala18 in
PfPKG) is conserved in the AIS of apicomplexan PKGs. This
adds weight to the notion that the Plasmodium AIS performs an
autoinhibitory function similar to the inhibitory segment (IS) in
PKA (18) and AIS in mammalian PKG, particularly in view of
the observable increase in basal activity (i.e., in the absence of
cGMP) of the truncated version of PfPKG missing this motif.
Although the domain-swapped dimer in our crystal structures
suggests the intriguing possibility of an intermolecular regulatory
system (in which each protomer extends N-terminal residues to
block the substrate-binding site of its dimeric partner), the to-
tality of our biochemical and biophysical data indicates cGMP-
free (i.e., inactive) Plasmodium PKG to be predominantly a
monomer. Accordingly, we were not able to detect trans-
inhibition between a full-length and a truncated form of
PfPKG, as illustrated in Fig. 2D. This suggests that the dimeric
interaction observed in our crystal structures is likely a crystal-
lographic artifact. Attempts to crystallize Plasmodium PKG in a
monomeric form have been unsuccessful, allowing us only to
speculate on how the AIS might mediate autoinhibition in mo-
nomeric PKG-III. We observe that in all available PKA holo-
enzyme structures, as well as in our Plasmodium PKG structures,
a short helix follows the inhibitory region and passes over the
long helix, connecting the first two CNBs. In comparing the two
PKG molecules in the dimer with the PKA structures (Fig. 2E),
we hypothesize that, as a monomer, this overpass would shift
over from position A to position B, thus enabling Plasmodium
PKG (and possibly other PKG-III enzymes in general) to me-
diate intrasteric inhibition in the same manner as PKA.
Interdomain Contacts Regulate the Function of Plasmodium PKG.
There are three types of interdomain interactions in Plasmodium
PKG: (i) contacts between the KD, CNB-A, and -B, which are
mostly conserved in PKA; (ii) contacts between CNB-D and KD
(including and particularly the participation of the two termini),
which are previously unrecognized and provide insight into how
cGMP activation may take place (see below); and (iii) arrangement
of connecting helices between all neighboring domains except for
CNB-A and -B, which suggests a mechanism in interdomain
communication in kinases. When some of these interactions were
abrogated by cGMP binding at one or more CNBs or by muta-
genesis, we observed significant protein aggregation, indicative of
their essential role in maintaining the structural integrity and
consequently the off state of PfPKG (SI Appendix, Table S2).
In PKA, the N-terminal helix may be phosphorylated and
myristoylated, with both posttranslational modifications affecting
the helical structure of αAK and the protein’s localization to
membranes (39). These sites are missing in Plasmodium PKG and
in mammalian type I PKG [type II PKG has been reported to be
myristoylated (40)]. Instead, αAK in Plasmodium PKG is a contact
interface for the two lobes of the KD, the C terminus and CNB-D,
keeping all these domains and subdomains in a mutually con-
straining arrangement. When cGMP binds CNB-D, at least some
of these contacts are expected to be abrogated or rearranged,
likely resulting in changes in αAK. This hypothesis is confirmed by
a study in which Kim et al. (23) identified the formation of a
capping triad (R484, Q532, and D533) in CNB-D when cGMP
enters its pocket; a comparison of our full-length structure and
their cGMP-bound structure (PDB ID code 4OFG) showed that,
in order for Q532 and D533 to form this triad and for R484 to
engage cGMP, helix αAK has to undergo noticeable displacement
(Fig. 4 C and D). To overcome stability issues of PKG in the
presence of cGMP, we produced isolated CNBs to capture cGMP-
dependent conformational changes in other CNBs. As such, we
report the cocrystallized PfCNB-A structure bound to cGMP,
which illustrates the reorganization of helix αCA upon cGMP ac-
tivation (Fig. 4E). The conformational alteration of this connect-
ing helix is expected to make a significant contribution to kinase
activity, as it makes important interactions with the kinase acti-
vation loop (K157–Y694 π-bond stabilization; Fig. 4F and SI Ap-
pendix, Table S2). The torsion of the connecting helix αCA is
reminiscent of cAMP-dependent activation by PKA, which uses a
similar mechanism to destabilize the extended αCA helix to un-
couple CNB-A and -B before dissociation of the complex (12).
Despite a lack of phosphorylation, the activation loop is in its
open (active) conformation. This is presumably necessary to allow
docking of the AIS. In kinase structures (including PKA) where
the activation loop is phosphorylated, T197 is extended by the
addition of phosphate such that it can engage the C-alpha helix, in
part to keep the activation loop in the stable conformation. In our
structures, the function of the phosphate is instead replaced by
interaction with CNB-A (SI Appendix, Fig. S7B).
A Structural Relay Model for Activation of Plasmodium PKG. In
Plasmodium parasites, stringent timing is required for cGMP-
mediated events, including egress of merozoites (41) and gam-
etes (4) from erythrocytes. A key trigger in the regulation of this
timing is cooperative binding of cGMP and activation of PKG—
a property confirmed by the sigmoidal shape of the activity
curves of our samples and a Hill coefficient of 1.9 observed in
our experiments. Whereas cooperativity in PKA is conferred by
the additional constraints imposed in the tetrameric holoenzyme
(13), our data indicate that, in Plasmodium PKG, and likely
PKG-IIIα in general, it is mediated by a network of connecting
helices which enables the binding of cGMP at CNB-D to facili-
tate binding at CNB-B and -A and ultimately removes all in-
hibitory constraints from the KD. Specifically, we propose the
following mechanism of cooperative activation (a sequence that
may also represent four potential stable or metastable states of
PfPKG). (i) When cGMP and ATP concentrations are low, all
three functional CNBs and the ATP-binding site are ligand-free.
The substrate-binding site of the KD is occupied by the AIS. This
is the totally autoinhibited state of PfPKG. (ii) As the level of
cGMP rises, the domain with the highest affinity, CNB-D,
becomes occupied first, resulting in a series of conformational
changes that involves displacement of αAK. This releases the N
lobe of the KD from some of its constraints. PfPKG is only ba-
sally active in this state because the AIS continues to inhibit the
KD, and the C lobe remains constrained by the first two CNBs.
PfPKG (with ATP) with cGMP-bound CNB-D may be a struc-
turally metastable state, one that is primed to engage cGMP at
CNB-B. (iii) The movement initiated at CNB-D is propagated to
pCNB-C via the connecting helix between the domains. In return,
this propels movement of the helix shared by CNB-B and pCNB-
C, allowing it to be recruited by CNB-B as the capping helix as
cGMP moves in, thus initiating bending of the helical bridge be-
tween CNB-A and -B in a manner seen in PKA and enabling
binding of cGMP to CNB-A. (iv) Binding of cGMP in CNB-A
disrupts interactions between this domain and the KD, including
the hydrophobic stack. This can release the AIS from its auto-
inhibitory position and the C lobe from all constraints, and free
the KD, which is already in its active conformation.
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Collectively, our structural-relay model of cooperative activa-
tion proposes that cGMP-mediated activation of Plasmodium
PKG involves a series of conformational changes, initiated by
binding to CNB-D, which are propagated around the pentagonal
molecule in a relay-like manner, increasing the affinity for cGMP
at CNB-B and, ultimately, CNB-A. Binding at three sites leads to
a fully active KD in a yet-to-be-determined structural arrange-
ment of the active full-length protein.
Materials and Methods
Protein Expression and Purification. Synthetic DNA for PfPKG and PvPKG from
Genscript (sequences are in SI Appendix) was amplified by PCR and subcloned
into the pFBOH-MHL vector—a baculovirus expression vector with an N-terminal
Hexa-Histag followed by a TEV cleavage site (https://www.thesgc.org/reagents/
vectors). Individual PfCNB domains (CNB-A, -AB, -C, and -D) were subcloned into
the pET15-MHL vector—a bacterial expression vector with an N-terminal Hexa-
Histag followed by a TEV cleavage site. PfPKG mutants were cloned by using a
described method (42) and expressed and purified as described above.
For protein expression, recombinant viral DNA was generated by transformation
of the resulting plasmid into DH10Bac Escherichia coli competent cells. This was in
turn transferred into Sf9 insect cells by using Cellfectin transfection reagent (Life
Technologies, Inc.). The insect cells were grown in HyQ SFX insect serum-free me-
dium (Thermo Fisher Scientific, Inc.), infected with 15 mL of P3 viral stocks per 0.8 L
of suspension cell culture, and incubated at 27 °C by using a platform shaker at
100 rpm. The cells were collected at 60- to 72-h postinfection, washed once with
phosphate-buffered saline (PBS), and transferred to buffer A (25 mMHepes, pH 7.5,
500 mM NaCl, 5% glycerol, and 5 mM imidazole). Individual PfCNB domains were
produced in E. coli BL21 (DE3) grown in Terrific Broth medium supplemented with
ampicillin (100 μg/mL) at 37 °C and induced for overexpression at 18 °Cwith 0.5mM
isopropyl β-D-1-thiogalactopyranoside by using a LEX bubbling system. Cells
were incubated for 1 h at room temperature in the presence of 10% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate followed by 5 min
of sonication by using a dual-horn sonicator (pulse length set to 15 s on and
20 s off). The total cell lysate was centrifuged at 16,000 × g for 1 h at 4 °C,
and soluble fractions were collected. Protein samples were purified by using
affinity chromatography (nickel beads; Sigma). The His-tagged PKG con-
structs were eluted with buffer A containing 250 mM imidazole. The eluted
protein was then subjected to size-exclusion chromatography using an
ÄKTAxpress system equipped with a Superdex 200 26/60 column on a system
(GE Healthcare) preequilibrated in buffer A.
Crystallography. PfPKG, PvPKG, and PvPKG–AMPPNP were set up in sitting-
drop vapor-diffusion experiments at room temperature (18 °C). All proteins
yielded quality-diffraction crystals in a concentration range of 10–15 mg/mL.
PfPKG was crystallized in the C2221 space group in 0.4 M L-proline, 10%
poly(ethylene glycol) (PEG) 3350, 0.1 M Hepes (pH 7.8), and 15% ethylene
glycol. PvPKG was crystallized in the C2 space group in 10% PEG 5000 mono-
methyl ether, 5% tascimate, 0.1 M Hepes, 15 mM spermidine (pH 7.0), and
25% glycerol. PvPKG–AMPPNP was crystallized in the C2 space group in 18.2%
PEG 3350, 0.1 M Hepes (pH 7.0), 0.1 M succinate, 2 mM MgCl2, and 5 mM
AMPPNP. PfCNB-D was cocrystallized in the C2221 space group with 1 mM
cGMP in 25% PEG 33350, 0.2 M NaCl, and 0.1 M Hepes (pH 7.5).
For PfPKG (apo form) and PvPKG–AMPPNP (cocrystal), data were collected
at beamline 19ID of the Argonne National Laboratory’s Advanced Photon
Source (http://www.sbc.anl.gov/index.html) and processed by using HKL-
3000 (43). For PvPKG (apo form), data were collected at beamline 23ID
and processed by using XDS (44). Finally, the PfCNBD–cGMP (cocrystal) data
were collected on a home-source X-ray diffractometer (Rigaku FR-E Super-
Bright rotating anode generator) and processed by using HKL3000 (43). The
PvPKG structure was solved by using the molecular-replacement pipeline
program BALBES (45). One KD in the asymmetric unit was found by using the
program, with additional weak density in the lattice clearly showing addi-
tional beta sheets and alpha helices. A C-α backbone trace was made into
the weak density. The models for the four CNBs were created by using
FFAS03 (46). In an iterative process, the CNB models were manually driven
into the backbone traces, and then real-space rigid-body refinement was
used in the program Coot (47) to more accurately generate the coordinates.
After each CNB was located, a round of REFMAC (48) was run, resulting in
improved electron-density maps that enabled placement of the next do-
main. Loops and side-chain placements not matching the electron density
were removed before refinement, and the overall model was built manually
by using Coot. The PfPKG structure was solved by using Phaser for molecular
replacement and the PvPKG coordinates as a search model. Both PfPKG and
PvPKG structures were refined by using REFMAC (49) to final R factors of
20.4% and 21.2%, respectively. The PvPKG–AMPPNP structure was de-
termined by refining the previously determined PvPKG apo structure against
the data acquired from the isomorphous complex crystals. Refinement was
carried out by using Buster (50) and REFMAC (49) combined with iterative
manual model building using the molecular graphics program Coot (47) to a
final R factor of 22.1%. The PfCNBD–cGMP structure was solved by using
Phaser for molecular replacement using the CNB-D domain coordinates from
PfPKG as a search model; the structure was refined by using REFMAC to a
final R factor of 19.6%. The geometry of the final models was checked by
using MolProbity (51) for reasonable clash scores and no Ramachandran
outliers. Crystallographic details and refinement statistics are summarized in
SI Appendix, Table S2. All of the illustrations in this work were generated by
using MacPymol (Schrödinger, LLC). The coordinates have been deposited in
the NCBI protein structure database [https://www.ncbi.nlm.nih.gov/protein;
PDB ID codes 5DYL (PvPKG), 5DYK (PfPKG), and 5DZC (PvPKG–AMPPNP)].
Enzymatic Assays. Kinase activity was characterized by using an NADH/ATPase
coupled assay (52). The reactions were performed at 25 °C in a 384-well plate
by using the Synergy 4 plate reader (Biotek). The reaction mix typically
contained the enzyme at a concentration of 250 nM, 500 μM Peptide 7
(RRRAPSFYAK), 150 μM NADH, 300 μM phosphoenolpyruvate, 1 mM ATP, a
lactate dehydrogenase/pyruvate kinase mix from Sigma (3 units/mL), 20 mM
Hepes (pH 7.5), 30 mM NaCl, 10 mMMgCl2, 1 mM CaCl2, 1 mM dithiothreitol,
and 0.01% Tween 20. The reaction was started by adding cGMP (0–200 μM)
and monitored for 1 h by using the rate of NADH absorbance decrease at
340 nm, which is proportional to the rate of ATP hydrolysis.
ITC. The binding constant and thermodynamic parameters of cGMP binding to
the CNB domains of PfPKG were assessed by using a nano-isothermal titration
calorimeter (TA Instruments). Experiments with PfCNB-A, -AB, -C, and -D were
performed at 25 °C. The sample cell was filled with 169 μL of purified protein
samples prepared at a concentration of 60 μM in buffer A [25 mM Hepes, pH
7.5, 300 mM NaCl, and 0.5 mM Tris(2-carboxyethyl)phosphine (TCEP)] and
stirred constantly at 350 rpm. The syringe was filled with 50 μL of cGMP at a
concentration of 0.7 mM in buffer A and titrated into the sample cell by using
3-μL injections at 180-s intervals. The net binding data were fitted by using the
NanoAnalyze Software (TA Instruments) to calculate the binding parameters.
Analytical Ultracentrifugation. Sedimentation equilibrium analytical ultra-
centrifugation experiments were performed by using an Optima XL-A ana-
lytical ultracentrifuge (Beckman). Protein samples at concentrations of 0.4,
0.8, and 1.2 mg/mL were prepared in a buffer containing 25 mM Hepes
(pH 7.5), 150mMNaCl, and 1mMTCEP. The sampleswere spun for 36h at 6,000;
8,000; and 10,000 rpm by using an An-60 Ti analytical rotor until equilibrium
was reached at 4 °C. Absorbance was monitored at 280 nm. The partial
specific volume, solvent density, and solvent viscosity were estimated by
using the Sednterp program (University of New Hampshire; server located at
http://rasmb.org/sednterp/). Data analysis was done with the Origin MicroCal
XL-A/CL-I Data Analysis Software Package (Version 4.0).
Multiangle Light Scattering. The molecular size of purified PfPKG was measured
at 25 °C by using a Viscotek Tetra detection system equipped with detectors for
static light scattering, UV, and refractive index (Malvern Instruments) connected
downstream of a size-exclusion chromatography system with a Superdex 200 HR
10/30 column mounted. The column was equilibrated in Equilibrium Buffer
(25mMHepes, 150mMNaCl, and 0.5mM TCEP). Protein samples and the bovine
serum albumin standard were dialyzed overnight against Equilibration Buffer.
Protein was diluted to a concentration of 6 mg/mL. A volume of 100 μL of both
was sequentially injected by using an auto-sampler into the chromatography
system at a flow rate of 0.2 mL/min. Molar weight determination was performed
by using the Omnisec software (Malvern Instruments).
P. falciparum Culture and Preparation of Soluble Protein Extracts. Transgenic P.
falciparum clone 3D7/PfPKG-HA-3A (27) was grown in A+ erythrocytes (Na-
tional Blood Transfusion Service) according to standard procedures (53) and
synchronized by multiple sorbitol treatments (54). Late schizont-stage parasites
were released from red blood cells by using 0.15% saponin in PBS and washed
twice in PBS. The parasite pellet was resuspended in hypotonic lysis buffer (5 mM
Tris·HCl, pH 8.0) and frozen at −80 °C. All buffers were supplemented with
protease inhibitors (cOmplete protease inhibitor mixture; Roche). The lysate was
thawed and centrifuged at 16,000 × g for 15 min. The supernatant containing
the soluble protein fraction was analyzed by native polyacrylamide gel electro-
phoresis (PAGE) and immunoblotting.
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Native Gel Electrophoresis and Immunoblotting. Protein samples were mixed
with 2× native sample buffer (62.5 mM Tris·HCl, pH 6.8, 25% glycerol, and
1% Bromophenol blue ± DTT) or sodium dodecyl sulfate/PAGE sample
buffer + DTT and resolved on an 8% Tris·HCl (pH 8.8) polyacrylamide gel run
in Tris·glycine buffer (pH 8.3) for 3 h at 150 V in an ice/water bath or on an
8% Tris.HCl (pH 8.8) polyacrylamide gel run in Tris.glycine SDS buffer (pH
8.3), respectively. Proteins were transferred to nitrocellulose and the PfPKG-
HA fusion protein visualized with anti-hemagglutinin antibody (clone 3F10,
Roche; diluted to 1:3,000) followed by horseradish peroxidase-conjugated
anti-rat (catalog no. SC-2006, Santa Cruz; at 1:6,000). The blot was reacted
with enhanced chemiluminescence plus substrate (Pierce) and exposed to X-
ray film.
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